glp-1 drug liraglutide may protect against dementia Older help brains of Alzheimer's patients Long-Term Effects Of GLP-1s: Risks

K.YuenN

Brazil Maintains Rapid Growth with Healthcare Market Development Revenue from obesity GLP-1 treatment in Brazil is growing at a CAGR of 28.9%, driven by expanding private health insurance coverage and increasing physician adoption of obesity pharmacotherapy

40 Qualitative studies exploring the service user experience of weight gain describe people with psychosis being catapulted into obesity and rapid and uncontrollable weight gain at an early stage of treatment

Nature 499 , 444449 (2013) Jazayeri, A

Both groups had a mean age of 56 and were nearly 62% female

Cagrilintide (AM833) Cagrilintide is a long-acting amylin analog designed for once-weekly (OW) SC administration (based on the structure of natural amylin), developed by Novo Nordisk [112]